Wednesday - February 4, 2026
Datroway Granted Priority Review in the US as 1st-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Who are Not Candidates for Immunotherapy
February 04, 2026
WILMINGTON, Delaware, Feb. 4 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

DATROWAY(R) (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo's DATROWAY significantly improved overall survival vs. chemother . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products